TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8077066

Group type: EXPERIMENTAL
Intervention: Single dose oral nicorandil (5, 10, 20, or 30 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 2684380

Group type: EXPERIMENTAL
Intervention: Buspirone (5 mg) administered BID, titrated to optimal dose
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg) administered BID, titrated to optimal dose
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 1189985

Group type: EXPERIMENTAL
Intervention: Glycerol infusion
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no glycerol infusion)
Number of subjects: 106
Study: 31280641

Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 136
Study: 29225332

Group type: EXPERIMENTAL
Intervention: Endotoxin (0.8 ng/kg lipopolysaccharide iv)
Number of subjects: 15
Study: 25449994

Group type: EXPERIMENTAL
Intervention: Dolutegravir alone, fasting
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dolutegravir with calcium carbonate, fasting
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dolutegravir with ferrous fumarate, fasting
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dolutegravir with calcium carbonate or ferrous fumarate with a moderate-fat meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dolutegravir administered 2 hours before calcium carbonate or ferrous fumarate, fasting
Number of subjects: 24
Study: 23377194

Group type: EXPERIMENTAL
Intervention: drospirenone-ethinyl estradiol (DEE)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: drospirenone-ethinyl estradiol + metformin (M)
Number of subjects: 42
Study: 22018267

Group type: EXPERIMENTAL
Intervention: Motor Learning Walking Program (MLWP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Body-weight-supported treadmill training (BWSTT)
Number of subjects: 70
Study: 19222055

Group type: EXPERIMENTAL
Intervention: Non-contact therapeutic touch intervention (experimental group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sound of a metronome set at a steady slow pace (placebo group)
Number of subjects: 90
Study: 16865075

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg/kg/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl (5 microg/kg bolus)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 40
Study: 15560936

Group type: EXPERIMENTAL
Intervention: Eating disorders group (15 young women)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy control group (15 healthy women)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Eating disorders group (subgroup analysis)
Number of subjects: 15
Study: 11192275

Group type: EXPERIMENTAL
Intervention: Follow-up of cardiovascular events and deaths reported by GPs every 2 years.
Number of subjects: 7735

Group type: EXPERIMENTAL
Intervention: Questionnaires mailed to surviving subjects.
Number of subjects: 7735

Group type: EXPERIMENTAL
Intervention: Mortality reporting from dual sources.
Number of subjects: 7735
Study: 9308799

Group type: EXPERIMENTAL
Intervention: Inhibin A
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Inhibin B
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Activin A
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Follicular fluid androstenedione/oestradiol ratios
Number of subjects: 47
Study: 8294627

Group type: EXPERIMENTAL
Intervention: NPSV (Non-invasive pressure support ventilation)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: NIPPV (Non-invasive intermittent positive pressure ventilation in assist-control mode)
Number of subjects: 29

Group type: COMPARATOR
Intervention: NMV (Non-invasive mechanical ventilation)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (Standard medical therapy alone)
Number of subjects: 29
Study: 3555040

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg orally every 12 hours for a mean duration of 9.6 days (six to 18 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cefotaxime 2.0 g intravenously every eight hours for a mean duration of 9.3 days (five to 14 days)
Number of subjects: 60
Study: 31626906

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1493
Study: 30580277

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with tourniquet
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia without tourniquet
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: General anaesthesia with tourniquet
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: General anaesthesia without tourniquet
Number of subjects: 400
Study: 27397921

Group type: COMPARATOR
Intervention: 1-minute heart rate recovery after peak exercise performance
Number of subjects: 47

Group type: COMPARATOR
Intervention: Composite fitness score (including measures of strength, flexibility, and aerobic fitness)
Number of subjects: 47
Study: 24453485

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Minimal acupuncture (MA)
Number of subjects: 15
Study: 22302665

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids applied with a squirt system
Number of subjects: 32

Group type: COMPARATOR
Intervention: Topical corticosteroids applied with a nasal spray
Number of subjects: 32
Study: 20675173

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (including diet and physical exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical training based on endurance and/or resistance exercises
Number of subjects: 0
Study: 18756885

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass graft (OPCAB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass graft (CABG)
Number of subjects: 60
Study: 15742410

Group type: EXPERIMENTAL
Intervention: r-hepatitis B vaccine (BEVAC)
Number of subjects: 166

Group type: COMPARATOR
Intervention: ENGERIX-B (commercial control)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 166
Study: 12822626

Group type: EXPERIMENTAL
Intervention: Sole therapy TMR
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: TMR with coronary artery bypass grafting
Number of subjects: 81

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting only (control group)
Number of subjects: 81
Study: 10722237

Group type: EXPERIMENTAL
Intervention: Diabetic lesions (tumor necrosis factor-alpha expression)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nondiabetic lesions (tumor necrosis factor-alpha expression)
Number of subjects: 20
Study: 7720988

Group type: EXPERIMENTAL
Intervention: 4-ASA (2 g)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5-ASA (1 g)
Number of subjects: 50
Study: 2041662

Group type: EXPERIMENTAL
Intervention: Dexamethasone adjunctive treatment
Number of subjects: 160
Study: 7209734

Group type: EXPERIMENTAL
Intervention: Radionuclide left ventricular ejection fraction (LVEF) during graded supine bicycle exercise
Number of subjects: 14
Study: 30157532

Group type: EXPERIMENTAL
Intervention: Liraglutide (≤1.8 mg daily)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 1260
Study: 30883686

Group type: EXPERIMENTAL
Intervention: Targeting an arterial partial pressure of oxygen (PaO2) of 8 kPa
Number of subjects: 2928

Group type: COMPARATOR
Intervention: Targeting an arterial partial pressure of oxygen (PaO2) of 12 kPa
Number of subjects: 2928
Study: 26403465

Group type: EXPERIMENTAL
Intervention: Monthly dihydroartemisinin-piperaquine (DHA/PQ)
Number of subjects: 176

Group type: COMPARATOR
Intervention: No chemoprevention
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Monthly dihydroartemisinin-piperaquine (DHA/PQ) with low PQ exposure
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Monthly dihydroartemisinin-piperaquine (DHA/PQ) with medium PQ exposure
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Monthly dihydroartemisinin-piperaquine (DHA/PQ) with high PQ exposure
Number of subjects: 176
Study: 23638438

Group type: EXPERIMENTAL
Intervention: Pesticide exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Having an additional job off the farm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous injury
Number of subjects: 0
Study: 22087077

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAPQ)
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy (ASAQ)
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 4116

Group type: COMPARATOR
Intervention: Chlorproguanil-dapsone-artesunate (CD+A)
Number of subjects: 4116
Study: 18831979

Group type: EXPERIMENTAL
Intervention: Weight gainers (males)
Number of subjects: 2753

Group type: EXPERIMENTAL
Intervention: Weight losers (males)
Number of subjects: 2753

Group type: EXPERIMENTAL
Intervention: Weight gainers (females)
Number of subjects: 2753

Group type: EXPERIMENTAL
Intervention: Weight losers (females)
Number of subjects: 2753

Group type: COMPARATOR
Intervention: Weight maintainers (females)
Number of subjects: 2753
Study: 17690340

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus strain GG
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Mix of four bacterial strains (L delbrueckii var bulgaricus, Streptococcus thermophilus, L acidophilus, and Bifidobacterium bifidum)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Oral rehydration solution (control group)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Enterococcus faecium SF68
Number of subjects: 571
Study: 15331124

Group type: EXPERIMENTAL
Intervention: Dexamethasone or hydrocortisone co-incubation
Number of subjects: 93

Group type: COMPARATOR
Intervention: LPS stimulation
Number of subjects: 93
Study: 11306905

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (110‐285 IU/kg/day) administered via continuous intravenous infusion after surgery until mobilization the next day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (150‐199 IU/kg/day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (200‐285 IU/kg/day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 68
Study: 9442423

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% triclosan, 2% copolymer, 1100 ppm F from 0.243% sodium fluoride)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control dentifrice (identical to test group but without triclosan/copolymer)
Number of subjects: 60
Study: 7899035

Group type: EXPERIMENTAL
Intervention: Expanding dynamic random-dot patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotating dynamic random-dot patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Translating dynamic random-dot patterns
Number of subjects: 0
Study: 3232799

Group type: COMPARATOR
Intervention: Fentanyl 0 micrograms/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fentanyl 2 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fentanyl 5 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fentanyl 15 micrograms/kg
Number of subjects: 80
Study: 2371371

Group type: EXPERIMENTAL
Intervention: Morning light at 10,000 lux for 30 minutes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Evening light at 10,000 lux
Number of subjects: 24

Group type: COMPARATOR
Intervention: Morning light at 3,000 lux
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2,500 lux treatment for 2 hours (previous studies)
Number of subjects: 24
Study: 1095308

Group type: EXPERIMENTAL
Intervention: Pizotifen (BC 105)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31670808

Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg plus Azithromycin 1 g
Number of subjects: 279

Group type: COMPARATOR
Intervention: Ceftriaxone 500 mg plus Azithromycin 1 g
Number of subjects: 279
Study: 31134866

Group type: EXPERIMENTAL
Intervention: Rural Response System using Community-Based Action Teams 'COMBAT' for preventing VAW
Number of subjects: 3280

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 3280
Study: 28780886

Group type: EXPERIMENTAL
Intervention: Verbal landing instruction
Number of subjects: 24

Group type: COMPARATOR
Intervention: No verbal landing instruction
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bipodal landing
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Unipodal landing
Number of subjects: 24
Study: 24972643

Group type: EXPERIMENTAL
Intervention: Alcohol and drug addictions
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Realistic opinion about the causes and treatment of schizophrenia, anxiety, bulimia, and depression
Number of subjects: 360
Study: 23558598

Group type: EXPERIMENTAL
Intervention: Hemodynamic treatment based on impedance cardiography
Number of subjects: 128
Study: 21108561

Group type: EXPERIMENTAL
Intervention: Serum NT‐proBNP measurement
Number of subjects: 4264

Group type: EXPERIMENTAL
Intervention: Serum NT‐proBNP measurement corrected for hs‐CRP
Number of subjects: 4264

Group type: EXPERIMENTAL
Intervention: Serum hs‐CRP measurement
Number of subjects: 4264

Group type: EXPERIMENTAL
Intervention: Serum hs‐CRP measurement corrected for NT‐proBNP
Number of subjects: 4264

Group type: EXPERIMENTAL
Intervention: Serum hs‐CRP adjusted for cardiovascular risk factors
Number of subjects: 4264

Group type: EXPERIMENTAL
Intervention: Serum NT‐proBNP adjusted for cardiovascular risk factors
Number of subjects: 4264
Study: 19845417

Group type: EXPERIMENTAL
Intervention: Vigabatrin treatment (Group I)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Vigabatrin withdrawal (Group II)
Number of subjects: 734

Group type: COMPARATOR
Intervention: No vigabatrin treatment (Group III)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Combined Groups I and II
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Duration of vigabatrin therapy
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Mean daily dose of vigabatrin
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Static perimetry vs kinetic perimetry
Number of subjects: 734
Study: 17238670

Group type: EXPERIMENTAL
Intervention: RuleEd web-based editing environment
Number of subjects: 0
Study: 15507097

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Pangramin SLIT; 0.5 microg major allergens, three times per week for 32 months
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 11136681

Group type: EXPERIMENTAL
Intervention: Local administration of enoxaparin during predilation with reduced systemic heparinization
Number of subjects: 100

Group type: COMPARATOR
Intervention: Systemic heparinization
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Local administration of enoxaparin
Number of subjects: 100
Study: 9232300

Group type: EXPERIMENTAL
Intervention: 1.1 MAC isoflurane
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 0.6 MAC isoflurane
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Albuterol (2 puffs)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (2 puffs)
Number of subjects: 67
Study: 8124904

Group type: EXPERIMENTAL
Intervention: Daily morning administration of prednisolone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alternate-day administration of prednisolone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Corticosteroid treatment in patients with GCA
Number of subjects: 44
Study: 3301614

Group type: EXPERIMENTAL
Intervention: Lactitol enemas
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lactose enemas
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lactitol and lactose enemas
Number of subjects: 45

Group type: COMPARATOR
Intervention: Tap-water enemas
Number of subjects: 45
Study: 30982843

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) - 155 units, 31 injections
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA)
Number of subjects: 179
Study: 27770336

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Casting
Number of subjects: 32
Study: 26503066

Group type: EXPERIMENTAL
Intervention: Phosphatidylethanol (PEth)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Carbohydrate-deficient transferrin (CDT)
Number of subjects: 160
Study: 23288418

Group type: EXPERIMENTAL
Intervention: Group A (0.7 ml/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group B (0.6 ml/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group C (0.5 ml/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard contrast protocol with test bolus technique
Number of subjects: 90
Study: 21769850

Group type: EXPERIMENTAL
Intervention: Imatinib 200 mg administered twice a day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18382907

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 211
Study: 16879825

Group type: EXPERIMENTAL
Intervention: Endometrial stromal cells from patients with deep infiltrating endometriosis
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Endometrial stromal cells from patients with ovarian endometriosis
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Endometrial stromal cells from patients with superficial peritoneal endometriosis
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control endometrial tissue samples from fertile women
Number of subjects: 99
Study: 12567339

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine (5 microg/mL) instilled for 20 seconds
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine (5 microg/mL) instilled for 60 seconds
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ilioinguinal and iliohypogastric block with 0.25% bupivacaine with epinephrine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Normal saline 0.25 mL/kg instilled for 20 or 60 seconds
Number of subjects: 103
Study: 10469751

Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 2091
Study: 8700737

Group type: EXPERIMENTAL
Intervention: Nurse-led unit
Number of subjects: 71

Group type: COMPARATOR
Intervention: Medically managed care
Number of subjects: 71
Study: 1832904

Group type: EXPERIMENTAL
Intervention: Classical CMF (cyclophosphamide/methotrexate/5‐fluorouracil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous CMF (modified 3-weekly schedule)
Number of subjects: 0
Study: 6349648

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium (200 mg initially, then 100 mg every 4 hours for 24 hours, followed by 100 mg every 8 hours for 6 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Indometacin (25 mg initially, then 25 mg every 4 hours for 24 hours, followed by 50 mg every 8 hours for 6 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Indometacin
Number of subjects: 20
Study: 30563481

Group type: EXPERIMENTAL
Intervention: Intervention group with good quality implementation of physical activity breaks, implemented by teachers with high self-efficacy and good previous knowledge about the intervention.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intervention group with unsatisfying quality of implementation and low previous knowledge about the intervention.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intervention group with fewer physical activity breaks combined with other conditions.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (27 classes).
Number of subjects: 51
Study: 27655755

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 2000 IU/d
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cholecalciferol 400 IU/d
Number of subjects: 57
Study: 24548977

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22555530

Group type: EXPERIMENTAL
Intervention: Ozonated oil applied to surgical wound
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-ozonated oil (control)
Number of subjects: 20
Study: 20964865

Group type: EXPERIMENTAL
Intervention: 20 ml/day anti‐inflammatory dose fish oil (3.6 g eicosapentaenoic acid, 2.4 g docosahexanoic acid)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 20 ml/day low dose fish oil (0.36 g eicosapentaenoic acid, 0.24 g docosahexanoic acid)
Number of subjects: 150
Study: 18719436

Group type: EXPERIMENTAL
Intervention: Intraoperative acceleromyographic monitoring
Number of subjects: 185

Group type: COMPARATOR
Intervention: Qualitative train‐of‐four (TOF) monitoring
Number of subjects: 185
Study: 15990174

Group type: EXPERIMENTAL
Intervention: Hyaluronate receptor (CD44) expression during relapses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Integrin alpha4 (CD49d) expression during relapses
Number of subjects: 24
Study: 12727401

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open haemorrhoidectomy
Number of subjects: 0
Study: 9450771

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNbeta-1a; AVONEX), 30 microg once weekly by intramuscular injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNbeta-1a; AVONEX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (active patients with gadolinium enhancement at baseline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNbeta-1a; AVONEX) (active patients with gadolinium enhancement at baseline)
Number of subjects: 0